Efficacy and Safety of Roxadustat in Patients with Chronic Kidney Disease: An Updated Meta-Analysis of Randomized Controlled Trials including 6,518 Patients

Table 1

Baseline characteristics of studies included in the meta-analysis.

Study	Country	Blinded	Patients	Comparator	Sample size	No. of experimental	No. of comparator	Duration (weeks)
Chen et al. [3]	China	Open-label	DD	Epoetin alfa	304	204	100	27
Hou et al. [9]	China	Open-label	PD	ESAs	129	86	43	24
Akizawa et al. [10]	Japan	Double-blind	HD	Darbepoetin	303	151	152	24
Csiky et al. [6]	Europe	Open-label	DD	ESAs	836	415	421	104
Chen et al. [11]	China	Double-blind/open-label	NDD/DD	Placebo/epoetin alfa	91/96	61/74	30/22	8/6
Provenzano et al. [12]	USA	Open-label	HD	Epoetin alfa	144	108	36	19
Provenzano et al. [13]	USA	Open-label	DD	Epoetin alfa	1043	522	521	52
Barratt et al. [14]	UK	Open-label	NDD	Darbepoetin alfa	616	323	293	104
Charytan et al. [15]	USA	Open-label	DD	Epoetin alfa	741	370	371	52
Akizawa et al. [16]	Japan	Open-label	NDD	Darbepoetin alfa	332	201	131	52
Chen et al. [17]	China	Double-blind	NDD	Placebo	152	101	51	8
Shutov et al. [18]	Russia	Double-blind	NDD	Placebo	594	391	203	104
Akizawa et al. [19]	Japan	Double-blind	NDD	Placebo	107	80	27	6
Besarab et al. [20]	USA	Single-blind	NDD	Placebo	116	88	28	12
Coyne et al. [8]	USA	Double-blind	NDD	Placebo	922	616	306	52

DD: dialysis-dependent; NDD: not dialysis-dependent; PD: peritoneal dialysis; HD: hemodialysis.